

To: Business Editor (For immediate release)



**STRATEGIC COOPERATION WITH WAL-MART IN CHINA
TO FURTHER EXPAND THE DISTRIBUTION OF “MAGIC 美即”SERIES**

(Hong Kong, 10 April 2006) – Followed by the announcement of successful cooperation with Carrefour in China on 29 March, 2006, **Hua Han Bio-Pharmaceutical Holdings Limited** (“Hua Han” or the “Group”)(Stock Code: 587), a leading manufacturer of naturally sourced gynecological medicines and medicinal healthcare products for women, today announced strategic cooperation with another leading retailer, Wal-Mart in China, to further expand the distribution of **“Magic 美即”** Series.

The Group has successfully signed a contract with Wal-Mart to distribute its **“Magic 美即”** series products in Wal-Mart’s approximately 50 chain stores in China, which are located in 22 major cities including Beijing, Shanghai, Chongqing, Guangzhou, Shenzhen and other cities. **“Magic 美即”** series are expected to begin the distribution in Wal-Mart’s chain stores before May 2006.

Mr. Deng Jie, Chief Executive Officer of Hua Han, said, “With the recent distribution agreements with Carrefour and Wal-Mart, in addition to the current cooperation with Watsons, the Group is confident that **“Magic 美即”** series will further increase the market share and brand awareness, and result in greater benefits to the Group. The Group also believes that the robust growth of **“Magic 美即”** series will help the Group to further implement business strategies and capture more opportunities in expanding into diversified business segments with high profit margin.”

— End —

About Hua Han Bio-Pharmaceutical Holdings Limited

Hua Han Bio-Pharmaceutical Holdings Limited is a leading manufacturer of a range of naturally sourced gynecological medicines and medicinal healthcare products for women. Hua Han is NOT a generic drug producer. Capitalizing on China’s huge pharmaceutical market, Hua Han has enjoyed robust growth in both turnover and net profit in the past 4 years. Moreover, its quality products and proprietary production technology are unrivaled in the marketplace. In addition to its extensive gynecological specialist network, Hua Han has a strong focus on R&D and various strategic alliances with distinguished medical research institutions in China and Hong Kong. Furthermore, Hua Han has a nationwide sales and distribution network with offices in 29 major provinces and municipalities in China and direct distribution channels to over 3,000 hospitals, 70,000 drugstores and 2,000 supermarkets. Hua Han has recently formed a strategic alliance with Haw Par Corporation Limited, which is a Singapore-listed multinational pharmaceutical enterprise. The Group was listed on the Main Board of the Stock Exchange of Hong Kong Limited on 10 December 2002.